---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295423393.md"
description: "Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma."
datetime: "2026-08-10T14:40:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295423393.md)
  - [en](https://longbridge.com/en/news/295423393.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295423393.md)
generator: "portal-rs"
---

# 

Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.

### Related Stocks

- [IPHA.US](https://longbridge.com/en/quote/IPHA.US.md)

## Related News & Research

- [Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III](https://longbridge.com/en/news/295412578.md)
- [Innate Pharma prices private placement of new shares at EUR 1.7 each](https://longbridge.com/en/news/296394400.md)
- [Bpifrance Participations, Innate Pharma board director, purchases EUR 3 million of Innate Pharma shares](https://longbridge.com/en/news/295958260.md)
- [Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy](https://longbridge.com/en/news/295419917.md)
- [Innate Pharma Secures €30M, Extends Cash Runway Into 2028](https://longbridge.com/en/news/295966041.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**